guidelines, visit NCCN. org). A challenge in clinical practice is that TP53 test results may not be available at the time of adjuvant therapy, as occurred in the present case. A genetics evaluation may take a substantial amount of time, particularly if the
Search Results
A Young Woman With Bilateral Breast Cancer: Identifying a Genetic Cause and Implications for Management
Monique A. de Bruin, James M. Ford, and Allison W. Kurian
Impact of the 7th Edition AJCC Staging Classification on the NCCN Clinical Practice Guidelines in Oncology for Gastric and Esophageal Cancers
Vivian E. Strong, Thomas A. D’Amico, Lawrence Kleinberg, and Jaffer Ajani
primary surgical therapy with or without adjuvant therapy, and others preferring neoadjuvant therapy followed by surgery. Medically fit patients with T3 and T4a tumors should undergo neoadjuvant therapy after completion of staging by laparoscopy and
Adjuvant Chemotherapy After Lobectomy for T1–2N0 Non–Small Cell Lung Cancer: Are the Guidelines Supported?
Paul J. Speicher, Lin Gu, Xiaofei Wang, Matthew G. Hartwig, Thomas A. D'Amico, and Mark F. Berry
-based chemotherapy in node-negative non-small cell lung cancer . J Thorac Oncol 2012 ; 7 : 963 – 972 . 14. Zornosa C Mamet R Reid M . Utilization of adjuvant therapy among completely resected non-small cell lung cancer (NSCLC) patients in the National
Initiation of Trastuzumab by Women Younger Than 64 Years for Adjuvant Treatment of Stage I–III Breast Cancer
Huei-Ting Tsai, Claudine Isaacs, Filipa C. Lynce, Suzanne C. O'Neill, Chunfu Liu, Marc D. Schwartz, Nandini Selvam, Yingjun Zhou, and Arnold L. Potosky
first 9 months after diagnosis; most of the 156 women without continuous coverage had ≥6 months of coverage after their breast cancer diagnosis. Measures The outcome of the study was receipt of trastuzumab as adjuvant therapy for stage I–III HER2
Cotreatment of Hairy Cell Leukemia and Melanoma With the BRAF Inhibitor Dabrafenib
James S. Blachly, Gerard Lozanski, David M. Lucas, Michael R. Grever, Kari Kendra, and Leslie A. Andritsos
patient is now 23 months from his first melanoma recurrence, with no evidence of melanoma. The impact of BRAF inhibitors as adjuvant therapy for melanoma is unknown and currently being studied in phase III trials ( ClinicalTrials.gov identifiers: NCT
Delays in Diagnosis and Treatment of Breast Cancer: A Safety-Net Population Profile
Kshama Jaiswal, Madelyne Hull, Anna L. Furniss, Reina Doyle, Natalia Gayou, and Elizabeth Bayliss
with the manufacturers of any products discussed in this article or their competitors. References 1. Desai S Hurley J Takita C . Impact of surgery-radiation interval on locoregional outcome in patients receiving neo-adjuvant therapy and
EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance
Michael Cecchini, Jeffrey Sklar, and Jill Lacy
neoadjuvant FOLFIRINOX followed by pancreaticoduodenectomy with negative margins and 6 cycles of adjuvant FOLFIRINOX. Surgical pathology revealed ypT3N1Mx (stage IIB) adenocarcinoma. Eight months after completion of adjuvant therapy, PET imaging revealed
Contemporary Intravesical Treatment Options for Urothelial Carcinoma of the Bladder
Stephen A. Brassell and Ashish M. Kamat
Meyer R . A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin . J Urol 1996 ; 156
Uptake of the 21-Gene Assay Among Women With Node-Positive, Hormone Receptor−Positive Breast Cancer
Megan C. Roberts, Allison W. Kurian, and Valentina I. Petkov
hospital . J Surg Oncol 2015 ; 111 : 203 – 207 . 10.1002/jso.23794 8. Eiermann W , Rezai M , Kümmel S , . The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast
Exceptional Response to Olaparib in a Patient With Recurrent Ovarian Cancer and an Entire BRCA1 Germline Gene Deletion
Megan Randall, Kelly Burgess, Lela Buckingham, and Lydia Usha
diagnosed with stage III poorly differentiated ovarian adenocarcinoma in 2007. Initial treatment consisted of a total abdominal hysterectomy with bilateral salpingo-oophorectomy followed by adjuvant therapy with 6 cycles of carboplatin and docetaxel. She
